|
|
Volumn 148, Issue 4, 2003, Pages 784-788
|
|
Alefacept therapy produces remission for patients with chronic plaque psoriasis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEFACEPT;
HYBRID PROTEIN;
IMMUNOSUPPRESSIVE AGENT;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
CHRONIC DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
FOLLOW UP;
HUMAN;
MIDDLE AGED;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PSORIASIS;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
RETREATMENT;
TIME;
TREATMENT OUTCOME;
ADOLESCENT;
ADULT;
AGED;
CHRONIC DISEASE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
FOLLOW-UP STUDIES;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MIDDLE AGED;
PSORIASIS;
RECOMBINANT FUSION PROTEINS;
REMISSION INDUCTION;
RETREATMENT;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 0038824717
PISSN: 00070963
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2133.2003.05239.x Document Type: Article |
|
Times cited : (68)
|
|
References (0)
|
